J&J Escapes $482 Million Jury Verdict Over Heart Devices

The U.S. Supreme Court refused to revive a $482 million jury verdict against Johnson & Johnson (JNJ) over disputed heart devices, rejecting an appeal by a doctor who said the company infringed his patent.

The justices today left intact a federal appeals court decision that overturned the verdict. The appeals court said the judge overseeing the trial misinterpreted Bruce Saffran’s patent and that, under the correct definition of key terms, J&J’s Cordis unit wasn’t using his invention.

The January 2011 jury award was the ninth-largest patent verdict in U.S. history, according to data compiled by Bloomberg. With more than $111 million in interest, the amount J&J was told to pay reached $593.4 million.

Saffran’s patent deals with ways to treat injured tissue with the use of a permeable barrier. He claimed the invention was incorporated into Cordis’s Cypher stents, tiny mesh tubes that prop open heart arteries after they are cleared of fat.

J&J, the company that pioneered the market for heart stents, exited the business in 2011. J&J is based in New Brunswick, New Jersey.

The case is Saffran v. Johnson & Johnson, 13-405.

To contact the reporters on this story: Greg Stohr in Washington at gstohr@bloomberg.net; Susan Decker in Washington at sdecker1@bloomberg.net

To contact the editors responsible for this story: Patrick Oster at poster@bloomberg.net; Bernard Kohn at bkohn2@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.